Ligand Targretin

NDA for bexarotene capsules submitted June 23 for second-line treatment of early-stage cutaneous T-cell lymphoma, refractory or persistent early CTCL and refractory late-stage CTCL. Ligand, which already markets Ontak (denileukin diftitox) for CTCL, requested a priority review for the orphan indication